Insider · CIK 0001369091
W Anthony Vernon
Files at MKC (MCCORMICK & CO INC), NVCR (NovoCure Ltd), NUVB (Nuvation Bio Inc.). First filing Jun 4, 2025, latest Jun 3, 2026.
In brief
W Anthony Vernon files SEC Form 4 as director at NVCR (NovoCure Ltd), and also at MKC (MCCORMICK & CO INC), NUVB (Nuvation Bio Inc.). Since Jun 4, 2025, W Anthony Vernon has reported 0 open-market buys worth $0 and 2 open-market sells worth $64k, the latest filed on Jun 3, 2026.
A track record needs three past buys with six months of prices behind them; W Anthony Vernon has 0, so none is measured yet.
The newest scored trade: sold $46k of NVCR on Jun 2, 2026, filed Jun 3, 2026, scored 36 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $46k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NVCR: NovoCure Ltd
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | NovoCure Ltd | $46k 2,945 shares | -1% | +58% from low-14% from high | |
| 30Weak | NovoCure Ltd | $17k 999 shares | -1% | +17% from low-49% from high |
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | NVCR NovoCure Ltd | AGrant or award Ordinary Shares | +11,610 | $0.00 | $0 | 209,267 | Jun 5, 2026 |
| Jun 3, 2026 | NVCR NovoCure Ltd | AGrant or award Stock Option (Right to Buy)derivative | +16,999 | $0.00 | $0 | 16,999 | Jun 5, 2026 |
| Jun 2, 2026 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -2,945 | $15.77 | $46k | 197,657 | Jun 3, 2026 |
| May 21, 2026 | NUVB Nuvation Bio Inc. | AGrant or award Stock Option (Right to Buy)derivative | +123,397 | $0.00 | $0 | 123,397 | May 26, 2026 |
| Apr 28, 2026 | NVCR NovoCure Ltd | MOption exercise Ordinary Shares | +21,500 | $11.39 | $245k | 200,602 | Apr 28, 2026 |
| Apr 28, 2026 | NVCR NovoCure Ltd | MOption exercise Stock Option (Right to Buy)derivative | -21,500 | $0.00 | $0 | 0 | Apr 28, 2026 |
| Feb 15, 2026 | MKC MCCORMICK & CO INC | MOption exercise Common Stock - Voting | +2,222 | - | - | 14,048 | Feb 18, 2026 |
| Feb 15, 2026 | MKC MCCORMICK & CO INC | MOption exercise Restricted Stock Unitsderivative | -2,222 | - | - | 0 | Feb 18, 2026 |
| Jun 4, 2025 | NVCR NovoCure Ltd | AGrant or award Ordinary Shares | +11,215 | $0.00 | $0 | 179,102 | Jun 6, 2025 |
| Jun 4, 2025 | NVCR NovoCure Ltd | AGrant or award Stock Option (Right to Buy)derivative | +16,697 | $0.00 | $0 | 16,697 | Jun 6, 2025 |
| Jun 3, 2025 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -999 | $17.35 | $17k | 167,887 | Jun 4, 2025 |
| May 21, 2025 | NUVB Nuvation Bio Inc. | AGrant or award Stock Option (Right to Buy)derivative | +292,983 | $0.00 | $0 | 292,983 | May 23, 2025 |
Questions about W Anthony Vernon
Answered from the filings on this page, as of the latest one.
Is W Anthony Vernon buying or selling?
In the last 12 months W Anthony Vernon reported 0 open-market buys worth $0 and 1 open-market sell worth $46k on SEC Form 4; the latest was sold $46k of NVCR on Jun 2, 2026. Grants, option exercises and tax withholding are not counted.
How did W Anthony Vernon's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and W Anthony Vernon has 0.
Where does W Anthony Vernon file Form 4?
W Anthony Vernon has filed Form 4 at NVCR (NovoCure Ltd); MKC (MCCORMICK & CO INC); NUVB (Nuvation Bio Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.